Skip to content

Evaluation of the Diagnostic Value of the TPD System in Determining ADHF Causing Acute Dyspnea

Evaluation of the Diagnostic Value of the TPD System in Determining ADHF Causing Acute Dyspnea

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03998410
Enrollment
130
Registered
2019-06-26
Start date
2019-09-15
Completion date
2021-07-01
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHF

Keywords

ADHF Dyspnea ED

Brief summary

The objective of this study is to evaluate Lung Doppler signals (LDS) among patients presenting to the emergency department with acute dyspnea, in order to determine the diagnostic value of this non-invasive method to discriminate ADHF causing dyspnea from any other cause i.e., non-ADHF causes of dyspnea.

Detailed description

Dyspnea (shortness of breath) is a common symptom affecting as many as 25% of patients seen in ambulatory settings. It can be caused by many different underlying conditions, some of which arise acutely and can be life-threatening, making rapid clinical evaluation and targeted diagnostic studies of central importance. A number of disorders cause dyspnea, including acute decompensated heart failure (ADHF), chronic obstructive pulmonary disease (COPD), asthma, pulmonary embolism, pneumonia, metabolic acidosis, neuromuscular weakness, and others. The overlapping clinical presentations of these conditions and comorbid diseases can make the diagnostic evaluation of dyspnea a significant challenge. Acute heart failure (AHF) is a major cause of serious morbidity and death in the general population and one of the most common medical causes of hospitalization among people aged over 60. Patients presenting to the ED with ADHF must be evaluated and treated rapidly to ensure the best possible outcomes. The diagnosis should be made as soon as possible and therapy initiated. Delayed diagnosis at presentation may also result in patients being inappropriately transferred to non-specialist wards, resulting in longer stays, increased re-admission and poorer outcomes. The key to improving the time to diagnosis depends on the clinical evaluation alongside a readiness to initiate relevant additional tests. Previous studies showed that the TPD has the potential to differentiate between the cardiac cause of dyspnea and any other cause.

Interventions

DEVICELung Doppler Signals

Recording Doppler ultrasound on the right chest wall

Sponsors

Echosense Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

Recording Doppler US signals over the right wall chest

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Patients with acute onset dyspnea (defined as shortness of breath (SOB) at rest or on exertion) and diagnostic uncertainty of etiology where heart failure is in consideration. * Patients designated to undergo chest X-ray as part of standard of care assessment.

Exclusion criteria

* Obvious trauma contributing to dyspnea * Inability to provide written informed consent * Not speaking English or Spanish * Right-sided lobectomy * Patients with implanted ventricular assist device * Patient is unable to undergo the TPD test * Patient is already enrolled in a clinical study with experimental medications

Design outcomes

Primary

MeasureTime frameDescription
Accuracy of diagnosisAverage of 1 yearoverall accuracy of the TPD system for the determination of ADHF causing acute dyspnea in an ED setting versus the gold standard (GS) diagnosis as determined by the final adjudicated diagnosis

Secondary

MeasureTime frameDescription
Sensitivity, Specificity, PPV, NPV of TPD diagnosisAverage of 1 yearCalculate the analysis success parameters

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026